Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2017

Open Access 01-12-2017 | Review

Platelets, diabetes and myocardial ischemia/reperfusion injury

Authors: Isabella Russo, Claudia Penna, Tiziana Musso, Jasmin Popara, Giuseppe Alloatti, Franco Cavalot, Pasquale Pagliaro

Published in: Cardiovascular Diabetology | Issue 1/2017

Login to get access

Abstract

Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and highly interconnected. A complex and entangled interaction is also emerging between platelet function, antiplatelet drugs, coronary diseases and ischemia/reperfusion injury, especially in diabetic conditions. Here we briefly summarize features of antiplatelet therapy in type 2 diabetes (T2DM). We also treat the influence of T2DM on ischemia/reperfusion injury and how anti-platelet therapies affect post-ischemic myocardial damage through pleiotropic properties not related to their anti-aggregating effects. miRNA-based signature associated with T2DM and its cardiovascular disease complications are also briefly considered. Influence of anti-platelet therapies and different effects of healthy and diabetic platelets on ischemia/reperfusion injury need to be further clarified in order to enhance patient benefits from antiplatelet therapy and revascularization. Here we provide insight on the difficulty to reduce the cardiovascular risk in diabetic patients and report novel information on the cardioprotective role of widely used anti-aggregant drugs.
Literature
1.
Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–44.PubMedCrossRef
2.
Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SRK, Forouhi NG, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: reykjavik prospective study and systematic review. PLoS Med. 2010;7:1–12.CrossRef
3.
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34. doi:10.​1056/​NEJM199807233390​404.PubMedCrossRef
4.
Mudaliar S. Intense management of diabetes mellitus: role of glucose control and antiplatelet agents. J Clin Pharmacol. 2004;44:414–22.PubMedCrossRef
5.
American Diabetes Association. Executive summary: standards of medical care in diabetes–2013. Diabetes Care. 2013;36(Suppl 1):S4–10. doi:10.​2337/​dc13-S004.
6.
Schrúor K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis aspirin causes a bleeding tendency that involves inhibition of platelet function and prostaglandin biosynthesis. 1997;23.
7.
Patrono C, Rocca B. Drug Insight: aspirin resistance—fact or fashion? Nat Clin Pract Cardiovasc Med. 2007;4(1):42–50.PubMedCrossRef
8.
9.
Mcadam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 (prostaglandins͞platelets͞monocytes͞ibuprofen͞celecoxib). Pharmacology. 1999;96:272–7.
10.
Homorodi N, Kovacs EG, Lee S, Katona E, Shemirani AH, Haramura G, et al. The lack of aspirin resistance in patients with coronary artery disease. J Trans Med. 2016;14:74.CrossRef
11.
Russo I, Viretto M, Barale C, Mattiello L, Doronzo G, Pagliarino A, et al. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes. 2012;61:2913–21.PubMedPubMedCentralCrossRef
12.
Close SL. Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant? Fundam Clin Pharmacol. 2012;26:19–26.PubMedCrossRef
13.
Marcucci R, Grifoni E, Giusti B. On-treatment platelet reactivity: state of the art and perspectives. Vasc Pharmacol. 2016;77:8–18.CrossRef
14.
Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol. 2011;72:619–33.PubMedPubMedCentralCrossRef
15.
Collaboration AT. Collaborative overview of randomised trials of antiplatelet. BMJ. 1994;308:235–46.CrossRef
16.
Antithrombotic Trialists’ Collaboration, Trialists A. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.CrossRef
17.
Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. JAMA. 2008;300:2134–41.PubMedCrossRef
18.
19.
Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.PubMedPubMedCentralCrossRef
20.
21.
Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230–5.PubMedCrossRef
22.
Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–5.PubMedCrossRef
23.
Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–5.PubMedCrossRef
24.
Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010. doi:10.​1016/​j.​jacc.​2010.​04.​047.
25.
Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17:110–6.PubMedCrossRef
26.
Małek LA, Witkowski A. Use of antiplatelet therapies during primary percutaneous coronary intervention for acute myocardial infarction. Interv Cardiol. 2010;2:705–18.CrossRef
27.
Cubero Gomez JM, Acosta Martinez J, Mendias Benitez C, Diaz De La Llera LS, Fernandez-Quero M, Guisado Rasco A, et al. VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel. Acta Cardiol. 2015;70:728–34.PubMed
28.
Zaccardi F, Pitocco D, Willeit P, Laukkanen JA. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials. Atherosclerosis. 2015;240:439–45.PubMedCrossRef
29.
Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College. Diabetes Care. 2010;33:1395–402. doi:10.​1016/​j.​jvn.​2010.​10.​002.PubMedPubMedCentralCrossRef
30.
Tamminen MK, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Insulin therapy improves insulin actions on glucose metabolism and aortic wave reflection in type 2 diabetic patients. Eur J Clin Invest. 2003;33:855–60.PubMedCrossRef
31.
Neergaard-Petersen S, Hvas A-M, Kristensen SD, Grove EL. Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes. Semin Thromb Hemost. 2016;42:234–41.PubMedCrossRef
32.
Drzewoski J, Watala C. Is aspirin resistance a real problem in people with type 2 diabetes? Diabetes Care. 2004;27:1245–6.PubMedCrossRef
33.
34.
Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J. 2007;28:1925–7. doi:10.​1093/​eurheartj/​ehm248.PubMedCrossRef
35.
Sacco RL, Sivenius J, Diener H-C. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol. 2005;62:403–8.PubMedCrossRef
36.
Angiolillo DJ, Bernardo E, Ramírez C, Costa MA, Sabaté M, Jimenez-Quevedo P, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006;48:298–304.PubMedCrossRef
37.
Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin e in type 2 diabetic patients. Diabetes Care. 2003;26:3264–72.PubMedCrossRef
38.
Roncaglioni MC, de Gaetano G. Collaborative group of the primary prevention project. low-dose aspirin and vitamin e in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89–95.CrossRef
39.
Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31–41.PubMedCrossRef
40.
41.
Shlomai G, Haran-Appel T, Sella T, Grossman Y, Hauschner H, Rosenberg N, et al. High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study. Cardiovasc Diabetol. 2015;14:80.PubMedPubMedCentralCrossRef
42.
Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005;42:99–103.PubMedCrossRef
43.
Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol. 2006;97:567–70.PubMedCrossRef
44.
Simpson SH, Abdelmoneim AS, Omran D, Featherstone TR. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. Am J Med. 2014;127:95.PubMedCrossRef
45.
Fitzgerald R, Pirmohamed M. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther. 2011;130:213–25.PubMedCrossRef
46.
Zhang D, Zhang X, Liu D, Liu T, Cai W, Yan C, et al. Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016;15:50.PubMedPubMedCentralCrossRef
47.
Feng X, Tucker KL, Parnell LD, Shen J, Lee YC, Ordovás JM, et al. Insulin receptor substrate 1 (IRS1) variants confer risk of diabetes in the Boston Puerto Rican Health Study. Asia Pac J Clin Nutr. 2013;22:150–9.PubMedPubMedCentral
48.
Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care. 2009;32:531–40.PubMedPubMedCentralCrossRef
49.
Schuette C, Steffens D, Witkowski M, Stellbaum C, Bobbert P, Schultheiss H-P, et al. The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. Cardiovasc. Diabetol. 2015;14:15.PubMedPubMedCentralCrossRef
50.
World Health Organization. Cardiovascular diseases (CVDs). Fact sheet No317, Sept. 2012. 2012. p. 4–7.
51.
52.
53.
Hausenloy DJ, Barrabes JA, Botker HE, Davidson SM, Di Lisa F, Downey J, et al. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016;111:70.PubMedPubMedCentralCrossRef
54.
Kleinbongard P, Skyschally A, Heusch G. Cardioprotection by remote ischemic conditioning and its signal transduction. Pflugers Arch. 2017;469:159–81.PubMedCrossRef
55.
Penna C, Granata R, Tocchetti CG, Gallo MP, Alloatti G, Pagliaro P. Endogenous cardioprotective agents: role in pre and postconditioning. Curr Drug Targets. 2015;16:843–67.PubMedCrossRef
56.
Cohen MV, Downey JM. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol. 2015;172:1913–32.PubMedCrossRef
57.
Penna C, Perrelli M-G, Pagliaro P. Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid Redox Signal. 2013;18:556.PubMedCrossRef
58.
Heusch G, Rassaf T. Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning??? Circ Res. 2016;119:676–95.PubMedCrossRef
59.
Bell RM, Bøtker HE, Carr RD, Davidson SM, Downey JM, Dutka DP, Heusch G, Ibanez B, Macallister R, Stoppe C, Ovize M, Redington A, Walker JM, Yellon DM. 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Res Cardiol. 2016;111(4):41. doi:10.​1007/​s00395-016-0558-1.PubMedPubMedCentralCrossRef
60.
Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014. doi:10.​1124/​pr.​113.​008300.PubMed
61.
Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal. 2011;14:781–90.PubMedPubMedCentralCrossRef
62.
Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005;54:2360–4.PubMedCrossRef
63.
Whittington HJ, Babu GG, Mocanu MM, Yellon DM, Hausenloy DJ. The diabetic heart: too sweet for its own good? Cardiol Res Pract. 2012;2012:845698.PubMedPubMedCentral
64.
Whittington HJ, Harding I, Stephenson CIM, Bell R, Hausenloy DJ, Mocanu MM, et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. Cardiovasc Res. 2013;99:694–704.PubMedPubMedCentralCrossRef
65.
Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes. 2007;56:127–36.PubMedCrossRef
66.
Wang B, Raedschelders K, Shravah J, Hui Y, Safaei HG, Chen DDY, et al. Differences in myocardial PTEN expression and Akt signalling in type 2 diabetic and nondiabetic patients undergoing coronary bypass surgery. Clin Endocrinol. 2011;74:705–13.CrossRef
67.
68.
del Valle HF, Lascano EC, Negroni JA. Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels. Cardiovasc Res. 2002;55:642–59.PubMedCrossRef
69.
Kersten JR, Montgomery MW, Ghassemi T, Gross ER, Toller WG, Pagel PS, et al. Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol. 2001;280:H1744–50.PubMed
70.
Hassouna A, Loubani M, Matata BM, Fowler A, Standen NB, Galinanes M. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc Res. 2006;69:450–8.PubMedCrossRef
71.
Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007;59:418–58.PubMedCrossRef
72.
Kereiakes DJ. Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial. Rev Cardiovasc Med. 2009;10:72–82.PubMedCrossRef
73.
Bangalore S, Toklu B, Kotwal A, Volodarskiy A, Sharma S, Kirtane AJ, et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ. 2014;349:g6419.PubMedPubMedCentralCrossRef
74.
Yang X-M, Liu Y, Cui L, Yang X, Liu Y, Tandon N, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther. 2013. doi:10.​1007/​s10557-012-6436-7.
75.
Yang X-M, Liu Y, Cui L, Yang X, Liu Y, Tandon N, et al. Platelet P2Y blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013;18:251–62.PubMedCrossRef
76.
Cohen MV, Downey JM. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered. J. Cardiovasc Pharmacol Ther. 2014;19:179–90.PubMedCrossRef
77.
Yang XM, Cui L, White J, Kuck J, Ruchko MV, Wilson GL, Alexeyev M, Gillespie MN, Downey JM, Cohen MV. Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion. Basic Res Cardiol. 2015;110(2):3. doi:10.​1007/​s00395-014-0459-0.PubMedPubMedCentralCrossRef
78.
Cohen MV, Yang XM, White J, Yellon DM, Bell RM, Downey JM. Cangrelor-mediated cardioprotection requires platelets and sphingosine phosphorylation. Cardiovasc Drugs Ther. 2016;30:229–32.PubMedCrossRef
79.
Bell RM, Sivaraman V, Kunuthur SP, Cohen MV, Downey JM, Yellon DM. Cardioprotective properties of the platelet p2y12 receptor inhibitor, cangrelor: protective in diabetics and reliant upon the presence of blood. Cardiovasc Drugs Ther. 2015;29:415–8.PubMedPubMedCentralCrossRef
80.
Yang BC, Virmani R, Nichols WW, Mehta JL. Platelets protect against myocardial dysfunction and injury induced by ischemia and reperfusion in isolated rat hearts. Circ Res. 1993;72:1181–90.PubMedCrossRef
81.
Yang B, Mehta P, Mehta JL. Platelet-mediated cardioprotective effect against ischemia-reperfusion injury in isolated rat hearts: role of platelet number and contribution of supernatant of aggregated platelets. J Cardiovasc Pharmacol Ther. 1998;3:23–8. doi:10.​1177/​1074248498003001​03.PubMedCrossRef
82.
Russo I, Femminò S, Barale C, Cavalot F, Tullio F, Penna C, et al. Platelets from poorly controlled type 2 diabetes subjects show an impaired ability to protect against the cardiac ischaemia/reperfusion injury. Abstr. 52nd EASD Annu. Meet. Munich: Diabetologia; 2016.
83.
Anfossi G, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care. 1998;21:121–6.PubMedCrossRef
84.
85.
Santilli F, Lapenna D, La Barba S, Davì G. Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. Free Radic Biol Med. 2015;80:101–10.PubMedCrossRef
86.
Lim HS, Blann AD, Lip GYH. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109:2524–8.PubMedCrossRef
87.
Soma P, Swanepoel AC, du Plooy JN, Mqoco T, Pretorius E. Flow cytometric analysis of platelets type 2 diabetes mellitus reveals “angry” platelets. Cardiovasc Diabetol. 2016;15:52.PubMedPubMedCentralCrossRef
88.
Soma P, Pretorius E. Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:96.PubMedPubMedCentralCrossRef
89.
Wang W, Lau WB, Wang Y, Ma X, Li R. Reduction of CTRP9, a novel anti-platelet adipokine, contributes to abnormal platelet activity in diabetic animals. Cardiovasc Diabetol. 2016;15:6.PubMedPubMedCentralCrossRef
90.
91.
92.
Hibi H, Yamada Y, Kagami H, Ueda M. Distraction osteogenesis assisted by tissue engineering in an irradiated mandible: a case report. Int J Oral Maxillofac Implants. 2006;21:141–7.PubMed
93.
Kubota S, Kawata K, Yanagita T, Doi H, Kitoh T, Takigawa M. Abundant retention and release of connective tissue growth factor (CTGF/CCN2) by platelets. J Biochem. 2004;136:279–82.PubMedCrossRef
94.
Lucarelli E, Beccheroni A, Donati D, Sangiorgi L, Cenacchi A, Del Vento AM, et al. Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials. 2003;24:3095–100.PubMedCrossRef
95.
Pieri L, Rinaldi B, Domenici L, Bacci S, Filippelli A, Capuano A, et al. Blood-borne cells involved in arterial repair upon experimental incision injury. Histol Histopathol. 2008;23:19–32.PubMed
96.
97.
Aiken JW, Shebuski RJ, Miller OV, Gorman RR. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J Pharmacol Exp Ther. 1981;219:299–308.PubMed
98.
Yee ES, Price DC, Aherne T, Ebert PA. Intracoronary platelet aggregation: pattern of deposition after ischemia, cardioplegia, and reperfusion. J Surg Res. 1986;40:499–503.PubMedCrossRef
99.
100.
Alloatti G, Montrucchio G, Emanuelli G, Camussi G. Platelet-activating factor (PAF) induces platelet/neutrophil co-operation during myocardial reperfusion. J Mol Cell Cardiol. 1992;24:163–71.PubMedCrossRef
101.
102.
Penna C, Perrelli M-G, Pagliaro P. Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxid Redox Signal. 2012;18:556.PubMedCrossRef
103.
104.
105.
106.
107.
Lin X, Tang X, Jiang Q, Liu Q, Lin Z, Lin J, et al. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. Clin Lab. 2012;58:539–44.PubMed
108.
Herová M, Schmid M, Gemperle C, Loretz C, Hersberger M. Low dose aspirin is associated with plasma chemerin levels and may reduce adipose tissue inflammation. Atherosclerosis. 2015;235:256–62.CrossRef
109.
Femminò S, Russo I, Cavalot F, Barale C, Tullio F, Penna C, Pagliaro P. Platelets Protect Against Myocardial Injury, but Platelets From Patients With Type 2 Diabetes Mellitus (T2DM) Lose their Protective Properties. Meeting Abstracts Ischemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery, May 12th–13th, 2016, Barcelona. J Mol Cell Cardiol. 2016;97:S1-8 Abstr 31
110.
Clancy L, Freedman JE. Blood-derived extracellular rna and platelet pathobiology: adding pieces to a complex circulating puzzle. Circ Res. 2016;118:374–6.PubMedPubMedCentralCrossRef
111.
112.
113.
Rome S. Are extracellular microRNAs involved in type 2 diabetes and related pathologies? Clin Biochem. 2013;46:937–45.PubMedCrossRef
114.
Binderup HG, Houlind K, Madsen JS, Brasen CL. Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width. Clin Biochem. 2016;49:1167–72.PubMedCrossRef
115.
Kok MGM, Mandolini C, Moerland PD, de Ronde MWJ, Sondermeijer BM, Halliani A, et al. Low miR-19b-1-5p expression in isolated platelets after aspirin use is related to aspirin insensitivity. Int J Cardiol. 2016;203:262–3.PubMedCrossRef
Metadata
Title
Platelets, diabetes and myocardial ischemia/reperfusion injury
Authors
Isabella Russo
Claudia Penna
Tiziana Musso
Jasmin Popara
Giuseppe Alloatti
Franco Cavalot
Pasquale Pagliaro
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2017
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-017-0550-6

Other articles of this Issue 1/2017

Cardiovascular Diabetology 1/2017 Go to the issue

Original investigation

Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndrome

Original investigation

Obesity and type 2 diabetes have additive effects on left ventricular remodelling in normotensive patients-a cross sectional study

Original investigation

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study

Original investigation

In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats

Original investigation

High density lipoprotein modulates osteocalcin expression in circulating monocytes: a potential protective mechanism for cardiovascular disease in type 1 diabetes

Original investigation

Advanced glycation end products induce brain-derived neurotrophic factor release from human platelets through the Src-family kinase activation

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits